IDEXX Laboratories, Inc. (IDXX) EV/FCF Ratio: 42.75x
Is IDEXX Laboratories, Inc.’s EV/FCF ratio high or low?
IDEXX Laboratories, Inc.'s EV/FCF ratio of 42.75x is 35% below its 5-year average of 65.95x, near the low end of its 5-year range (38.21x–111.13x).
As of Sunday, June 14, 2026. 24.04% below its 12-month average of 56.28x.
IDXX EV/FCF Ratio Chart
IDXX Average EV/FCF Ratio Chart
IDXX Current vs Average EV/FCF Ratio Chart
IDXX EV/FCF Ratio Metrics
EV/FCF RATIO
42.75x
EV/FCF RATIO AVG TTM
56.28x
EV/FCF RATIO AVG 3Y
56.87x
EV/FCF RATIO AVG 5Y
65.95x
EV/FCF RATIO AVG 10Y
69.17x
EV/FCF RATIO AVG 15Y
60.16x
EV/FCF RATIO AVG 20Y
54.56x
CURRENT VS TTM AVG
-24.04%
CURRENT VS 3Y AVG
-24.83%
CURRENT VS 5Y AVG
-35.18%
CURRENT VS 10Y AVG
-38.19%
CURRENT VS 15Y AVG
-28.94%
CURRENT VS 20Y AVG
-21.65%
IDXX Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 42.75x | 56.28x | 56.87x | 65.95x |
| Humana Inc. (HUM)vs › | $45.53B | 43.08x | 33.75x | 21.63x | 31.66x |
| Agilent Technologies, Inc. (A)vs › | $36.67B | 30.59x | 34.61x | 30.04x | 33.45x |
| Becton, Dickinson and Company (BDX)vs › | $52.98B | 18.30x | 23.34x | 27.93x | 30.73x |
| Cencora, Inc. (COR)vs › | $54.80B | 41.83x | 34.50x | 22.64x | 19.61x |
| Zoetis Inc. (ZTS)vs › | $33.36B | 19.15x | 28.04x | 41.96x | 48.22x |
| Centene Corporation (CNC)vs › | $32.19B | 4.32x | 9.55x | 24.73x | 19.03x |
| Medline Inc. (MDLN)vs › | $30.96B | 26.63x | 27.74x | 27.74x | 27.74x |
| IQVIA Holdings Inc. (IQV)vs › | $30.29B | 17.65x | 19.84x | 27.23x | 27.81x |
| Biogen Inc. (BIIB)vs › | $29.53B | 12.53x | 12.73x | 21.62x | 21.16x |
Cash Flow Valuation Comparison
EV/FCF
42.8x
P/FCF
41.9x
FCF Yield
2.39%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
IDEXX Laboratories, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The EV/FCF ratio for IDXX stock is 42.75x.
- Is IDEXX Laboratories, Inc.'s EV/FCF ratio high or low?
- IDEXX Laboratories, Inc.'s EV/FCF ratio of 42.75x is 35% below its 5-year average of 65.95x, near the low end of its 5-year range (38.21x–111.13x).
- What is the TTM average EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average EV/FCF ratio for IDXX stock is 56.28x.
- What is the 3Y average EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average EV/FCF ratio for IDXX stock is 56.87x.
- What is the 5Y average EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average EV/FCF ratio for IDXX stock is 65.95x.
- What is the 10Y average EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average EV/FCF ratio for IDXX stock is 69.17x.
- What is the 15Y average EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average EV/FCF ratio for IDXX stock is 60.16x.
- What is the 20Y average EV/FCF ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average EV/FCF ratio for IDXX stock is 54.56x.
IDEXX Laboratories, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-12 | 42.75x |
| 2026-06-11 | 42.52x |
| 2026-06-10 | 42.45x |
| 2026-06-09 | 44.09x |
| 2026-06-08 | 42.77x |
| 2026-06-05 | 42.84x |
| 2026-06-04 | 43.03x |
| 2026-06-03 | 42.74x |
| 2026-06-02 | 41.99x |
| 2026-06-01 | 43.19x |
| 2026-05-29 | 42.94x |
| 2026-05-28 | 43.28x |
| 2026-05-27 | 42.01x |
| 2026-05-26 | 42.47x |
| 2026-05-22 | 42.63x |
| 2026-05-21 | 42.16x |
| 2026-05-20 | 42.20x |
| 2026-05-19 | 41.67x |
| 2026-05-18 | 41.62x |
| 2026-05-15 | 40.35x |
| 2026-05-14 | 40.65x |
| 2026-05-13 | 40.34x |
| 2026-05-12 | 40.73x |
| 2026-05-11 | 40.59x |
| 2026-05-08 | 42.69x |
| 2026-05-07 | 43.59x |
| 2026-05-06 | 44.12x |
| 2026-05-05 | 42.90x |
| 2026-05-04 | 43.98x |
| 2026-05-01 | 44.31x |
| 2026-04-30 | 43.80x |
| 2026-04-29 | 43.25x |
| 2026-04-28 | 44.38x |
| 2026-04-27 | 44.88x |
| 2026-04-24 | 44.19x |
| 2026-04-23 | 43.81x |
| 2026-04-22 | 45.15x |
| 2026-04-21 | 44.43x |
| 2026-04-20 | 45.51x |
| 2026-04-17 | 45.98x |
| 2026-04-16 | 44.50x |
| 2026-04-15 | 45.33x |
| 2026-04-14 | 45.58x |
| 2026-04-13 | 44.81x |
| 2026-04-10 | 43.97x |
| 2026-04-09 | 45.64x |
| 2026-04-08 | 46.18x |
| 2026-04-07 | 44.87x |
| 2026-04-06 | 45.08x |
| 2026-04-02 | 44.47x |
| 2026-04-01 | 44.10x |
| 2026-03-31 | 43.88x |
| 2026-03-30 | 43.52x |
| 2026-03-27 | 43.61x |
| 2026-03-26 | 44.76x |
| 2026-03-25 | 44.94x |
| 2026-03-24 | 44.52x |
| 2026-03-23 | 45.16x |
| 2026-03-20 | 45.06x |
| 2026-03-19 | 45.26x |
| 2026-03-18 | 45.05x |
| 2026-03-17 | 45.81x |
| 2026-03-16 | 45.76x |
| 2026-03-13 | 44.80x |
| 2026-03-12 | 44.60x |
| 2026-03-11 | 46.84x |
| 2026-03-10 | 46.72x |
| 2026-03-09 | 47.60x |
| 2026-03-06 | 47.45x |
| 2026-03-05 | 48.25x |
| 2026-03-04 | 50.53x |
| 2026-03-03 | 49.53x |
| 2026-03-02 | 49.61x |
| 2026-02-27 | 51.15x |
| 2026-02-26 | 51.45x |
| 2026-02-25 | 51.20x |
| 2026-02-24 | 50.57x |
| 2026-02-23 | 48.57x |
| 2026-02-20 | 49.53x |
| 2026-02-19 | 54.31x |
| 2026-02-18 | 54.66x |
| 2026-02-17 | 53.92x |
| 2026-02-13 | 54.19x |
| 2026-02-12 | 53.17x |
| 2026-02-11 | 55.83x |
| 2026-02-10 | 55.65x |
| 2026-02-09 | 55.08x |
| 2026-02-06 | 55.48x |
| 2026-02-05 | 55.40x |
| 2026-02-04 | 55.34x |
| 2026-02-03 | 54.47x |
| 2026-02-02 | 55.06x |
| 2026-01-30 | 57.67x |
| 2026-01-29 | 58.20x |
| 2026-01-28 | 59.13x |
| 2026-01-27 | 59.73x |
| 2026-01-26 | 59.99x |
| 2026-01-23 | 59.65x |
| 2026-01-22 | 59.41x |
| 2026-01-21 | 59.87x |
| 2026-01-20 | 58.99x |
| 2026-01-16 | 61.47x |
| 2026-01-15 | 61.20x |
| 2026-01-14 | 61.06x |
| 2026-01-13 | 61.36x |
| 2026-01-12 | 62.27x |
| 2026-01-09 | 61.30x |
| 2026-01-08 | 61.22x |
| 2026-01-07 | 61.40x |
| 2026-01-06 | 60.75x |
| 2026-01-05 | 58.67x |
| 2026-01-02 | 57.63x |
| 2025-12-31 | 58.19x |
| 2025-12-30 | 58.68x |
| 2025-12-29 | 59.15x |
| 2025-12-26 | 59.20x |
| 2025-12-24 | 59.17x |
| 2025-12-23 | 58.67x |
| 2025-12-22 | 60.35x |
| 2025-12-19 | 60.20x |
| 2025-12-18 | 59.93x |
| 2025-12-17 | 59.80x |
| 2025-12-16 | 59.59x |
| 2025-12-15 | 60.22x |
| 2025-12-12 | 60.53x |
| 2025-12-11 | 60.81x |
| 2025-12-10 | 60.33x |
| 2025-12-09 | 60.09x |
| 2025-12-08 | 60.73x |
| 2025-12-05 | 61.36x |
| 2025-12-04 | 61.65x |
| 2025-12-03 | 62.36x |
| 2025-12-02 | 62.94x |
| 2025-12-01 | 62.62x |
| 2025-11-28 | 64.64x |
| 2025-11-26 | 64.91x |
| 2025-11-25 | 65.81x |
| 2025-11-24 | 64.58x |
| 2025-11-21 | 62.36x |
| 2025-11-20 | 59.27x |
| 2025-11-19 | 59.93x |
| 2025-11-18 | 57.65x |
| 2025-11-17 | 57.55x |
| 2025-11-14 | 59.32x |
| 2025-11-13 | 60.30x |
| 2025-11-12 | 61.32x |
| 2025-11-11 | 61.23x |
| 2025-11-10 | 60.98x |
| 2025-11-07 | 60.89x |
| 2025-11-06 | 61.33x |
| 2025-11-05 | 61.88x |
| 2025-11-04 | 62.04x |
| 2025-11-03 | 62.11x |
| 2025-10-31 | 67.23x |
| 2025-10-30 | 67.13x |
| 2025-10-29 | 67.04x |
| 2025-10-28 | 67.74x |
| 2025-10-27 | 69.10x |
| 2025-10-24 | 68.42x |
| 2025-10-23 | 68.18x |
| 2025-10-22 | 67.68x |
| 2025-10-21 | 68.03x |
| 2025-10-20 | 68.68x |
| 2025-10-17 | 67.85x |
| 2025-10-16 | 68.05x |
| 2025-10-15 | 68.24x |
| 2025-10-14 | 68.00x |
| 2025-10-13 | 67.63x |
| 2025-10-10 | 65.83x |
| 2025-10-09 | 67.15x |
| 2025-10-08 | 67.27x |
| 2025-10-07 | 67.00x |
| 2025-10-06 | 67.05x |
| 2025-10-03 | 67.41x |
| 2025-10-02 | 67.68x |
| 2025-10-01 | 66.25x |
| 2025-09-30 | 68.21x |
| 2025-09-29 | 67.34x |
| 2025-09-26 | 67.51x |
| 2025-09-25 | 66.04x |
| 2025-09-24 | 66.99x |
| 2025-09-23 | 69.20x |
| 2025-09-22 | 68.76x |
| 2025-09-19 | 70.02x |
| 2025-09-18 | 69.95x |
| 2025-09-17 | 68.42x |
| 2025-09-16 | 68.92x |
| 2025-09-15 | 68.75x |
| 2025-09-12 | 68.45x |
| 2025-09-11 | 68.87x |
| 2025-09-10 | 68.11x |
| 2025-09-09 | 69.96x |
| 2025-09-08 | 69.67x |
| 2025-09-05 | 68.64x |
| 2025-09-04 | 68.37x |
| 2025-09-03 | 67.70x |
| 2025-09-02 | 68.27x |
| 2025-08-29 | 69.07x |
| 2025-08-28 | 69.06x |
| 2025-08-27 | 68.42x |
| 2025-08-26 | 68.51x |
| 2025-08-25 | 68.47x |
| 2025-08-22 | 68.91x |
| 2025-08-21 | 67.60x |
| 2025-08-20 | 68.31x |
| 2025-08-19 | 67.98x |
| 2025-08-18 | 68.10x |
| 2025-08-15 | 69.46x |
| 2025-08-14 | 69.79x |
| 2025-08-13 | 70.83x |
| 2025-08-12 | 69.61x |
| 2025-08-11 | 69.59x |
| 2025-08-08 | 70.22x |
| 2025-08-07 | 69.38x |
| 2025-08-06 | 66.67x |
| 2025-08-05 | 68.53x |
| 2025-08-04 | 72.80x |
| 2025-08-01 | 53.44x |
| 2025-07-31 | 53.32x |
| 2025-07-30 | 57.02x |
| 2025-07-29 | 57.11x |
| 2025-07-28 | 56.47x |
| 2025-07-25 | 56.34x |
| 2025-07-24 | 54.85x |
| 2025-07-23 | 53.94x |
| 2025-07-22 | 53.10x |
| 2025-07-21 | 52.01x |
| 2025-07-18 | 51.39x |
| 2025-07-17 | 51.80x |
| 2025-07-16 | 51.98x |
| 2025-07-15 | 52.57x |
| 2025-07-14 | 53.04x |
| 2025-07-11 | 53.23x |
| 2025-07-10 | 53.98x |
| 2025-07-09 | 53.94x |
| 2025-07-08 | 53.76x |
| 2025-07-07 | 54.42x |
| 2025-07-03 | 54.56x |
| 2025-07-02 | 54.14x |
| 2025-07-01 | 54.14x |
| 2025-06-30 | 53.52x |
| 2025-06-27 | 53.03x |
| 2025-06-26 | 52.68x |
| 2025-06-25 | 52.94x |
| 2025-06-24 | 52.95x |
| 2025-06-23 | 52.38x |
| 2025-06-20 | 52.30x |
| 2025-06-18 | 51.91x |
| 2025-06-17 | 51.98x |
| 2025-06-16 | 52.78x |
| 2025-06-13 | 52.19x |
| 2025-06-12 | 52.60x |
| 2025-06-11 | 52.33x |
| 2025-06-10 | 52.50x |
| 2025-06-09 | 51.78x |
| 2025-06-06 | 52.40x |
| 2025-06-05 | 52.14x |
| 2025-06-04 | 52.40x |
| 2025-06-03 | 52.49x |
| 2025-06-02 | 51.41x |
Showing the most recent 260 of 4,826 data points. The chart above shows the full history.
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky